Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and-independent DR5 upregulation

Cell Death and Disease

Volumn 7, Issue 8, 2016, Pages

  Chen, Lei ^a   Meng, Yue ^a   Sun, Qi ^a   Zhang, Zhongyu ^a   Guo, Xiaoqing ^a   Sheng, Xiaotong ^a   Tai, Guihua ^a   Cheng, Hairong ^a   Zhou, Yifa ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME C; DEATH RECEPTOR 5; GINSENOSIDE; GINSENOSIDE CK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; GINSENOSIDE M1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; PATHOLOGY;

APOPTOSIS; AUTOPHAGY; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GINSENOSIDES; HCT116 CELLS; HT29 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84996602930     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.234     Document Type: Article

References (46)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682.
2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
4. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.
5. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821–830.
6. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–113.
7. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359–372.
8. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187–6194.
9. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450–3455.
10. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16: 1256–1263.
11. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/ TRAIL. Nat Med 2007; 13: 1070–1077.
12. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19: 5477–5486.
13. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G, Brady HJ. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 2006; 281: 5750–5759.
14. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11: 915–923.
15. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3: 409–416.
16. Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004; 279: 35829–35839.
17. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337–5345.
18. Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle 2012; 11: 3312–3323.
19. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011; 3: 86ra50.
20. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685–1693.
21. Hasegawa H, Sung JH, Huh JH. Ginseng intestinal bacterial metabolite IH901 as a new anti-metastatic agent. Arch Pharm Res 1997; 20: 539–544.
22. Chae S, Kang KA, Chang WY, Kim MJ, Lee SJ, Lee YS et al. Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem 2009; 57: 5777–5782.
23. Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH et al. Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol 2010; 30: 134–140.
24. Lee IK, Kang KA, Lim CM, Kim KC, Kim HS, Kim DH et al. Compound K, a metabolite of ginseng saponin, induces mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen species in human colon cancer cells. Int J Mol Sci 2010; 11: 4916–4931.
25. Kim AD, Kang KA, Kim HS, Kim DH, Choi YH, Lee SJ et al. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis 2013; 4: e750.
26. Di X, Zhang G, Zhang Y, Takeda K, Rosado LA, Zhang B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 2013; 4: 1349–1364.
27. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 2009; 69: 6581–6589.
28. Lee JC, Chou LC, Huang CH, Chung JG, Huang LJ, Lee KH et al. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells. Eur J Pharmacol 2011; 670: 96–104.
29. Prasad S, Yadav VR, Ravindran J, Aggarwal BB. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res 2011; 71: 538–549.
30. Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006; 66: 1740–1750.
31. Gupta SC, Reuter S, Phromnoi K, Park B, Hema PS, Nair M et al. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species-and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem 2011; 286: 1134–1146.
32. Tian X, Ye J, Alonso-Basanta M, Hahn SM, Koumenis C, Dorsey JF. Modulation of CCAAT/ enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286: 29408–29416.
33. Kim HK. Pharmacokinetics of ginsenoside Rb1 and its metabolite compound K after oral administration of Korean Red Ginseng extract. J Ginseng Res 2013; 37: 451–456.
34. Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol 2015; 5: 69.
35. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013; 4: e838.
36. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53–71.
37. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 2008; 4: 940–943.
38. Yuan BZ, Chapman J, Ding M, Wang J, Jiang B, Rojanasakul Y et al. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages. BMC Cancer 2013; 13: 140.
39. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 2005; 65: 5662–5667.
40. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005; 65: 6364–6370.
41. Lee JY, Jung KH, Morgan MJ, Kang YR, Lee HS, Koo GB et al. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther 2013; 12: 274–285.
42. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS et al. p53-dependent and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593–1598.
43. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141–143.
44. Kannappan R, Ravindran J, Prasad S, Sung B, Yadav VR, Reuter S et al. Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther 2010; 9: 2196–2207.
45. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK et al. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279: 40044–40052.
46. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254.